Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
7.09
+0.89 (14.35%)
At close: Oct 6, 2025, 4:00 PM EDT
7.10
+0.01 (0.14%)
After-hours: Oct 6, 2025, 7:54 PM EDT

Company Description

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.

The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.

Additionally, it is developing RAD301 and RAD302, which are Avβ6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic.

The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals.

The company was incorporated in 2021 and is based in Carlton, Australia.

Radiopharm Theranostics Limited
CountryAustralia
Founded2021
IndustryBiotechnology
SectorHealthcare
Employees14
CEORiccardo Canevari

Contact Details

Address:
62 Lygon Street, Level 3
Carlton, VIC 3053
Australia
Phone61 3 9824 5254
Websiteradiopharmtheranostics.com

Stock Details

Ticker SymbolRADX
ExchangeNASDAQ
Fiscal YearJuly - June
Reporting CurrencyAUD
CIK Code0001949257
ISIN NumberUS75041J1016
SIC Code2834

Key Executives

NamePosition
Riccardo CanevariMD, Chief Executive Officer and Director
Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICDFounder and Executive Chairman
Phillip HainsChief Financial Officer, Joint Company Secretary and Executive Director
Dr. Dimitris Voliotis M.D.Chief Medical Officer
Hitesh GoelHead of Project Management
Nathan Jong C.A.Joint Company Secretary

Latest SEC Filings

DateTypeTitle
Oct 1, 20256-KReport of foreign issuer
Sep 30, 20256-KReport of foreign issuer
Sep 18, 202520-FAnnual and transition report of foreign private issuers
Sep 17, 20256-KReport of foreign issuer
Sep 15, 20256-KReport of foreign issuer
Aug 29, 20256-KReport of foreign issuer
Aug 21, 20256-KReport of foreign issuer
Aug 1, 20256-KReport of foreign issuer
Jul 29, 20256-KReport of foreign issuer
Jul 28, 20256-KReport of foreign issuer